Leadership Overview
Eisai Global has 9 executives leading key functions including strategy, finance, information technology, quality assurance, and regional operations.
Driven by a human health care approach, Eisai Global focuses on developing and producing medicines that extend beyond traditional pharmaceutical services, emphasizing patient-centered healthcare solutions and significant research and development in the pharmaceutical sector.
Driven by a human health care approach, Eisai Global focuses on developing and producing medicines that extend beyond traditional pharmaceutical services, emphasizing patient-centered healthcare solutions and significant research and development in the pharmaceutical sector.
Leadership Roles at Eisai Global
Haruo Naito - Director, Representative Corporate Officer and Chief Executive Officer
Haruo Naito, the Director, Representative Corporate Officer and Chief Executive Officer at Eisai Global, directs the overarching corporate strategy and operational execution. Naito guides the company's commitment to a human health care approach, ensuring that pharmaceutical development and services prioritize patient well-being. This leadership role involves setting the strategic direction for research and development initiatives, particularly in areas demanding patient-centered solutions. Overseeing global operations, the Chief Executive Officer ensures alignment with Eisai's mission across North America, Europe, Asia Pacific, and the Middle East. Haruo Naito drives the company's business-to-business and business-to-consumer operations, fostering comprehensive healthcare delivery and pharmaceutical innovation. The Chief Executive Officer's strategic vision shapes Eisai's market impact and its dedication to advancing healthcare globally.
Tatsuyuki Yasuno - Chairman & Chief Executive Officer & Eisai Inc Region President (Americas)
Tatsuyuki Yasuno, the Chairman & Chief Executive Officer & Eisai Inc Region President (Americas) at Eisai Global, holds dual responsibilities for global leadership and regional operational oversight. Yasuno chairs the board, providing strategic guidance and governance for the entire organization. Concurrently, as Chief Executive Officer, this leader directs the company's core business functions and pharmaceutical development efforts. The role of Region President (Americas) involves direct management of operations within North America, ensuring strategic initiatives are effectively implemented and market presence is strengthened. Tatsuyuki Yasuno oversees the company's focus on research and development, particularly in patient-centered healthcare solutions within the Americas region. This executive drives Eisai's business-to-business and business-to-consumer operations, ensuring a comprehensive approach to healthcare delivery and pharmaceutical innovation across the Americas.
Rodney Dausch - Chief Financial Officer
Rodney Dausch, the Chief Financial Officer at Eisai Global, manages the company's financial strategy and fiscal operations. Dausch oversees all aspects of financial planning, budgeting, and reporting, ensuring robust fiscal health across global operations. This leadership position involves managing capital allocation for research and development, particularly for patient-centered healthcare solutions. The Chief Financial Officer directs investment strategies to support Eisai's expansion in North America, Europe, Asia Pacific, and the Middle East. Rodney Dausch ensures compliance with financial regulations and drives efficiency in business-to-business and business-to-consumer financial models. This executive's oversight is critical for sustaining Eisai's pharmaceutical manufacturing and development activities, supporting long-term growth and market stability.
Brian Harraka - Vice President & Chief Financial Officer
Brian Harraka, the Vice President & Chief Financial Officer at Eisai Global, supports the company's financial management and strategic fiscal planning. Harraka collaborates with the Chief Financial Officer to oversee financial reporting, treasury functions, and capital management. This role is integral to funding Eisai's extensive research and development in pharmaceutical manufacturing, with a focus on patient-centered healthcare solutions. The Vice President & Chief Financial Officer contributes to strategic financial decisions impacting operations across North America, Europe, Asia Pacific, and the Middle East. Brian Harraka ensures financial discipline across business-to-business and business-to-consumer segments, supporting the company's comprehensive approach to healthcare delivery. This executive's financial acumen is vital for Eisai's sustained growth and operational integrity.
Susumu Ebihara - President, Quality Cfu
Susumu Ebihara, the President, Quality Cfu at Eisai Global, leads the company's comprehensive quality assurance functions. Ebihara establishes and enforces stringent quality standards across all pharmaceutical manufacturing and development processes, ensuring product integrity and patient safety. This critical role oversees adherence to regulatory requirements and drives continuous improvement in quality management systems globally. The President, Quality Cfu ensures that Eisai's human health care approach is upheld through uncompromising quality standards in every product and service. Susumu Ebihara's leadership guarantees that patient-centered healthcare solutions meet the highest benchmarks for efficacy and safety. This executive's dedication to quality underpins Eisai's reputation for reliability and excellence in the pharmaceutical sector.
Toshimitsu Uenaka - President, Epochal Precision Anti-Cancer Therapeutics (Epat)
Toshimitsu Uenaka, the President, Epochal Precision Anti-Cancer Therapeutics (Epat) at Eisai Global, spearheads the company's advanced initiatives in oncology. Uenaka directs the research, development, and strategic deployment of precision anti-cancer therapeutics, focusing on innovative patient-centered solutions. This leadership position involves guiding cutting-edge scientific exploration and clinical trials to bring novel treatments to market. The President, Epochal Precision Anti-Cancer Therapeutics (Epat) ensures that Eisai's commitment to human health care is advanced through breakthroughs in cancer therapy. Toshimitsu Uenaka oversees the integration of these specialized treatments into the company's broader pharmaceutical development and healthcare delivery models. This executive's focus on precision oncology is vital for addressing unmet medical needs and enhancing patient outcomes.
Hiroyuki Murayama - President (Japan) & Promotion Department Manager, Product Strategy
Hiroyuki Murayama, the President (Japan) & Promotion Department Manager, Product Strategy at Eisai Global, leads the company's strategic product development and market promotion within Japan. Murayama oversees the formulation and execution of product strategies, ensuring alignment with Eisai's human health care approach and patient-centered objectives in the Japanese market. This dual role involves managing both the strategic direction of products and their effective promotion to healthcare providers and consumers. The President (Japan) ensures that Eisai's pharmaceutical manufacturing and development efforts in Japan meet global quality standards. Hiroyuki Murayama drives the successful launch and lifecycle management of key therapeutic agents, contributing significantly to the company's overall business model and market presence in Asia Pacific. This executive's leadership is pivotal for Eisai's success in its home market.
Kazuhiko Tamura - Vice President and President, Eisai Demand Chain Systems
Kazuhiko Tamura, the Vice President and President, Eisai Demand Chain Systems at Eisai Global, directs the optimization of the company's supply chain and distribution networks. Tamura oversees the end-to-end management of product flow, from manufacturing to patient delivery, ensuring efficiency and reliability across global operations. This leadership role is critical for supporting Eisai's pharmaceutical manufacturing and its commitment to patient-centered healthcare solutions. The President, Eisai Demand Chain Systems ensures seamless integration of logistics with business-to-business and business-to-consumer operations, enhancing accessibility to medicines. Kazuhiko Tamura's strategic oversight of the demand chain is fundamental to Eisai's operational effectiveness and its ability to meet market demands across North America, Europe, Asia Pacific, and the Middle East. This executive's focus on supply chain excellence supports the company's mission of delivering healthcare solutions.
Makoto Hoketsu - Vice President & Chief Information Officer
Makoto Hoketsu, the Vice President & Chief Information Officer at Eisai Global, directs the company's information technology strategy and infrastructure. Hoketsu oversees the development and implementation of digital solutions that support pharmaceutical manufacturing and research and development efforts. This leadership role ensures robust IT systems are in place to facilitate Eisai's human health care approach and patient-centered solutions. The Chief Information Officer manages technology initiatives across global operations, including North America, Europe, Asia Pacific, and the Middle East. Makoto Hoketsu drives the integration of technology within business-to-business and business-to-consumer operations, enhancing efficiency and data security. This executive's expertise is crucial for modernizing Eisai's operational framework and supporting its mission in healthcare delivery.
Explore Leadership Teams in Manufacturing
AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca is based in the United Kingdom.
Company Leadership
BeOne Medicines is a global biotechnology company focused on developing next-generation cancer treatments through innovative research and cutting-edge therapies. The company is committed to making these treatments accessible to patients worldwide, emphasizing speed, equity, and affordability in delivering care. Guided by the principle that cancer knows no borders, BeOne Medicines operates with a global perspective, striving to expand the reach of life-saving therapies and improve outcomes for patients everywhere.
Company Leadership
AR
AA
YY
Emcure Pharmaceuticals Limited is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products and healthcare solutions. Headquartered in Pune, India, the organization operates as an international pharmaceutical enterprise with a strong presence in both domestic and global healthcare markets. The company focuses on delivering innovative and affordable medicines that address a wide spectrum of medical conditions and therapeutic needs across the healthcare sector. The organization is driven by a research-focused strategy that emphasizes innovation, scientific advancement, and the development of effective therapeutic solutions. Through its research and development capabilities, Emcure Pharmaceuticals works to discover and formulate medicines that address unmet medical needs and improve patient outcomes. The company’s research initiatives focus on areas such as complex generics, biosimilars, biologics, and specialized pharmaceutical formulations. These research efforts allow the organization to continuously introduce improved therapies and drug delivery systems designed to enhance treatment effectiveness and patient safety.
Company Leadership SM
NS
Founded in 2005, Headquartered in Tokyo, Daiichi Sankyo is a global pharmaceutical company that develops and provides innovative new and generic medicines, as well as advanced drug discovery and delivery methods, serving patients in over 30 countries.
Company Leadership JN
KI
CB
HS
Frequently Asked Questions Regarding Eisai Global Top Executives and Leadership Team
